References to Primarv Literature
- WATSON RR: Prevention of immune dysfunction by dehydroepiandrosterone in ageing, chronic AIDS and leukaemia patients. Exp. Opin. Invest. Drugs (1995) 4:147–154.
- WATSON RR, CHARG 5, HULS A, ARAGHINIKNAM M: Dehydroepiandrosterone (DHEA) supplementation to prevent symptoms of ageing. Drugs Ageing. In press.
- SCIIWARTZ AG, PASHKO LL: Cancer prevention with dehydroepiandrosterone and Non-androgenic struc-tural analogs. J. Cell. Biochem. (1995) 22(Suppl.):210–217.
- PASHKO LL, SCHWARTZ AG: Reversal of food restriction-induced inhibition of mouse skin tumour promotion by adrenalectomy. Carcinogen esis (1992) 13:1925–1928.
- LANE MA, INGRAM DK, ROTH GS: Effects of ageing and long-term calorie restriction on DHEA and DHEA sulfate In rhesus monkeys. Ann. NY Acad. Sci. (1995) 774:319–322.
- SPITZ IM, BARDIN CW: Mifepristone (RU 486) a modula-tor of progestin and glucocorticoid action. New Engl. J. Med. (1993) 329:404–412.
- O'SHAUGHNESSY JA: Chemoprevention of breast can-cer. JAMA (1996) 275:1349–1353.
- GERUTT PA: Oxy-radicals and cancer. Lancet (1994)344:862–863.
- HURSTING SD, PERKINS SN, HAINES DC, WARD JM,PHANG JM: Chemoprevention of spontaneous tumori-genesis in p53-knockout mice. Cancer Res. (1995) 55:3949–3953.
- SCIIULZ S, NYCE JW: Inhibition of protein famesyltrans-ferase: a possible mechanism of tumour prevention by dehydroepiandrosterone sulfate. Carcinogenesis (1994) 15:2649–2652.
- LUBET RA, MCCORMICK DM, GORDON GM et al.: Effectsof dehydroepiamirosterone on 11CW-induced breast cancer in sprague-dawley rats. Ann. NY Acad. Sci. (1995) 774:340–341.
- KAWAI S, YAHATA N, NISHIDA S, NAGAI K, MIZUSHIMAY: Dehydroepiandrosterone inhibits B16 mouse mela-noma cell growth by induction of differentiation. Anti-cancer Res. (1995) 15:427–431.
- YEN SS, MORALES AJ, KHARRAM O: Replacement of DHEAIn ageing men and women. Potential remedial effects. Ann. IVY Acad. Sci. (1996) 774:128–142.
- MCLACHLAN JA, SERKIN CD, BAKOUCHE O: Dehydro-epiandrosterone modulation of lipopolysaccharide-stimulated monocyte cytotoxicity. J. Immunol. (1996) 156:328–355.
- ARANEO BA, WOODS ML II, DAYNES RA: Reversal of theimmunosenescent phenotype by dehydroepiandros-terone: hormone treatment provides an adjuvant effect on the immunisation of aged mice with recombinant hepatitis B surface antigen. J. Infect. Dis. (1993) 167:830–840.
- DANENBERG HD, BEN-YEHUDA A, ZAKAY-RONES Z, FRIEDMAN G: Dehydroepiandrosterone enhances influ-enza immunisation in aged mice. Ann. NY Acad. Sci. (1996) 774:297–299.
- ARANEO B, DAYNES R: Dehydroepiandrosterone func-tion as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinol-ogy (1995) 136:393–401.
- MEIKLE AW, DORCHUCK RW, ARANEO BA et al.: The presence of a dehydroepiandrosterone-specific recep-tor binding complex in murine T calf. Steroid Biochem Mol. Biol. (1992) 42:293–304.
- DANEHBERG HD, ALPERT G, LUSTIG S, BEN-NATHAN D.Dehydroepiandrosterone protects mice from endo-toxin toxicity and reduces tumour necrosis factor pro-duction. Antimicrob. Agents. Chemother. (1992) 36:2275–2279.
- OPOKU J, KALIMI M: Role of the antiglucocorticoid RU486 in the prevention of steroid-induced hypertension. Acta Endocrinol. (1992) 127:258–261.